Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
22.34
USD
|
+2.81%
|
|
+13.75%
|
-0.76%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
89.54
|
238.4
|
1,749
|
1,233
|
949.3
|
966.1
|
-
|
Enterprise Value (EV)
1 |
89.54
|
238.4
|
1,749
|
1,233
|
949.3
|
966.1
|
966.1
|
P/E ratio
|
-19.3
x
|
-28.4
x
|
-53.3
x
|
-15.5
x
|
-9.7
x
|
-11.1
x
|
13.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
3.22
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
3.22
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-33,366,415
x
|
-15,363,989
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
17,219
|
34,954
|
40,017
|
41,726
|
42,174
|
43,246
|
-
|
Reference price
2 |
5.200
|
6.820
|
43.70
|
29.54
|
22.51
|
22.34
|
22.34
|
Announcement Date
|
3/26/20
|
3/23/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
300
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.959
|
-6.446
|
-32.87
|
-80.02
|
-106
|
-100.3
|
150.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
50.07%
|
Earnings before Tax (EBT)
1 |
-4.631
|
-6.334
|
-32.38
|
-76.25
|
-97.22
|
-92.9
|
157.6
|
Net income
1 |
-4.631
|
-6.334
|
-32.38
|
-76.25
|
-97.22
|
-92.9
|
119.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
39.9%
|
EPS
2 |
-0.2700
|
-0.2400
|
-0.8200
|
-1.900
|
-2.320
|
-2.010
|
1.670
|
Free Cash Flow
|
-
|
-
|
-52.41
|
-80.23
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/23/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.753
|
-14.44
|
-17.82
|
-19.92
|
-21.34
|
-20.94
|
-26.51
|
-28.78
|
-27.88
|
-22.79
|
-23.8
|
-22.8
|
-25.3
|
-28.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.562
|
-14.17
|
-17.53
|
-19.33
|
-20.26
|
-19.13
|
-24.27
|
-26.38
|
-25.65
|
-20.92
|
-22
|
-20.9
|
-23.4
|
-26.5
|
Net income
1 |
-9.562
|
-14.17
|
-17.53
|
-19.33
|
-20.26
|
-19.13
|
-24.27
|
-26.38
|
-25.65
|
-20.92
|
-22
|
-20.9
|
-23.4
|
-26.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2400
|
-0.3500
|
-0.4400
|
-0.4800
|
-0.5100
|
-0.4700
|
-0.5800
|
-0.6300
|
-0.6100
|
-0.5000
|
-0.5100
|
-0.4800
|
-0.5400
|
-0.4800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
2/28/22
|
5/5/22
|
8/4/22
|
11/7/22
|
2/28/23
|
5/1/23
|
8/3/23
|
11/7/23
|
2/28/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-52.4
|
-80.2
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
22.2
|
2.71
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/23/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
Last Close Price
22.34
USD Average target price
124
USD Spread / Average Target +455.06% Consensus |
1st Jan change
|
Capi.
|
---|
| -0.76% | 966M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|